Study on Retroplacental Hematomas in Finistère (HEMOPLACENTA)

Retrospective Descriptive Study on Retroplacental Hematomas in Finistère

Cases with placental abruption will be identified by interrogation of two databases of Brest University Hospital between January 2013 and December 2018. First trimester PAPPA and bhCG levels will be recorded. PlGF levels will be measured in women with an available first trimester serum sample. Histological findings in placentas, course of pregnancies, maternal and fetal characteristics will described and compared between cases with and without placental chronic inflammation.

Study Overview

• Status: Completed
• Conditions: Placenta Diseases; Placental Abruption

Detailed Description

Identification of cases:

Placental abruption cases will be identified by interrogation of two databases of Brest University Hospital between January 2013 and December 2018.

The women diagnosed with placental abruption will be first identified by interrogation of the Medical Registry Department (MRD) of Brest University Hospital and of five other maternities of our county between January 2013 and December 2018, using the keyword "placental abruption".

Simultaneously, placental abruption cases will be identified from the Pathology department files of Brest University Hospital using a computerized database (ADICAP system).

Cases of placental abruption included in the study will be clinically defined and will not be only diagnosed by histological examination. All cases will be reviewed by an experienced obstetrician in order to confirm the diagnosis.

Duplicates, medical termination of pregnancy, marginal abruption, placenta previa, cases without histological examination of the placenta, histological cases without compatible clinical signs and cases from an unselected maternity will be excluded.

Women identified with placental abruption in the period of study will be sent an information letter explaining the study and its purpose. Women who express their opposition to participate to the study will be excluded.

Clinical parameters:

The following data will be recorded from medical files on a computerized database: baseline maternal characteristics including preconceptional Body Mass Index (BMI), tobacco use, drug use (cocaine, cannabis, buprenorphine) medical history (chronic hypertension, chronic nephropathy, diabetes, cardiovascular disease, autoimmune disease, previous venous thromboembolism), blood and rhesus group, obstetrical history, especially past vasculoplacental disorder and past placental abruption, age at delivery. The following pregnancy characteristics will also be collected: method of conception, medication during pregnancy (in particular aspirin and low molecular-weight heparin (LMWH)), gestational diabetes, premature rupture of membrane, pre-eclampsia (according to the American College of Obstetricians and Gynecologists' definition published in 2013, term at pre-eclampsia diagnosis, term at delivery and method of delivery, postpartum complications including postpartum hemorrhage (defined by a blood loss > 500 ml, whatever the mode of delivery), disseminated intravascular coagulation (DIVC), thromboembolic event after delivery and before hospital discharge, intensive care admission and length of stay.

The following fetal characteristics will be recorded: presence and term at diagnosis of intrauterine growth restriction (IUGR), stillbirth, birthweight and sex of the newborn. IUGR will be defined according to the 2013 French College of Obstetricians and Gynecologists guidelines by an estimated fetal weight below the 10th percentile using locally-accepted curve (AUDIPOG) associated with signs of fetal growth pathological restriction.

Placental parameters:

Histopathological examination of the placentas had been performed by two senior perinatal pathologists at Brest University Hospital. Histological findings were recorded by interrogation of the pathology computerized database APIX V7.

Placentas were fixed in 4% buffered formalin. Standard sampling of three blocks in the central area was performed and slides were Hematoxylin, Eosin and Saffron (HES) stained.

Recorded macroscopic findings will correspond to the following items: placenta weight, fetoplacental weight ratio, placental abruption, abnormal placental set-up (only circumvallation), abnormal umbilical cord (villamentous implantation, thin umbilical cord with < 0,8 cm in diameter, presence of a knot), presence and number of placental infarcts, intervillous thrombi and thrombi in a vessel of the chorionic plate affecting ≥ one third of the placental surface.

Recorded microscopic lesions will correspond to the following items according to Amsterdam consensus: maternal vascular malperfusion lesions such as microscopic infarcts, decidual arteriopathy, abnormal villous maturation (hypermature villi or villous agglutination), presence of fetal vascular malperfusion signs such as obliterative fetal vasculopathy or avascular villi, chorangiosis and erythroblastosis, excessive fibrin deposition, chronic inflammation such as villitis or chronic intervillositis of unknown etiology, chronic chorioamniotitis or chronic deciduitis, acute inflammation such as acute villitis, acute chorioamniotitis or funiculitis.

Biological parameters:

First trimester Down syndrome screening results will be collected for each pregnancy.

First trimester pregnancy associated plasma protein-A (PAPP-A) and β-human chorionic gonadotrophin (βhCG) levels had been measured in international unit/liter and converted to multiples of the median (MoM) using the crown-rump length or biparietal diameter measurement when the blood sample was obtained as an estimate of gestational age.

Available blood samples collected at the end of first trimester of pregnancy (between 11 weeks of gestation (WG) and 13+6 WG) for Down syndrome screening stored at -20°C in Biochemistry department of Brest University Hospital will be used for Placental Growth Factor (PlGF) quantification. Measurements will be done with the automated B.R.A.H.M.S KRYPTOR compact PLUS system (B.R.A.H.M.S PlGF plus KRYPTOR: Thermo Fisher Scientific, Hennigsdorf, Berlin) according to the manufacturer's instructions described elsewhere. PlGF levels will be expressed in pg/ml.

Informed written consents were obtained from women whose blood samples had been collected at the end of first trimester.

• Study Type: Observational
• Enrollment (Actual): 134

Contacts and Locations

Study Locations

• France
  • Brest, France, 29609
    • CHRU de Brest (médecine interne)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Pregnant women who had a placental abruption (clinically defined) with an available placental histological examination in one of 5 maternities of our county (Finistère, France) between January 2013 and December 2018.

Women identified with placental abruption in the period of study will be sent an information letter explaining the study and its purpose. Women who express their opposition to participate to the study will be excluded.

Description

Inclusion Criteria:

• Pregnant women
• who had a placental abruption (clinically defined)
• with an available placental histological examination
• in one of 5 maternities of our county (Finistère, France)
• between January 2013 and December 2018.

Exclusion Criteria:

• Medical termination of pregnancy
• marginal abruption
• placenta previa
• cases without histological examination of the placenta
• histological cases without compatible clinical signs
• cases from an unselected maternity.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Retrospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Cases with placental abruption; Cases of placental abruption included in our study will be clinically defined and will not be only diagnosed by histological examination. All cases will be reviewed by an experienced obstetrician in order to confirm the diagnosis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Histological findings in placentas n°1	placenta weight	through study completion, an average of one year
Histological findings in placentas n°2	presence of an histologic placental abruption	through study completion, an average of one year
Histological findings in placentas n°3	presence of an abnormal placental set-up	through study completion, an average of one year
Histological findings in placentas n°4	presence of an abnormal umbilical cord	through study completion, an average of one year
Histological findings in placentas n°5	presence of thrombi in the chorionic plate or intervillous thrombi	through study completion, an average of one year
Histological findings in placentas n°6	presence of maternal vascular malperfusion lesions such as macroscopic or microscopic infarcts, decidual arteriopathy or abnormal villous maturation	through study completion, an average of one year
Histological findings in placentas n°7	presence of fetal vascular malperfusion signs such as obliterative fetal vasculopathy or avascular villi	through study completion, an average of one year
Histological findings in placentas n°8	presence of chorangiosis or erythroblastosis	through study completion, an average of one year
Histological findings in placentas n°9	presence of excessive fibrin deposition	through study completion, an average of one year
Histological findings in placentas n°10	presence of chronic inflammation such as villitis or chronic intervillositis of unknown etiology, chronic chorioamniotitis or chronic deciduitis	through study completion, an average of one year
Histological findings in placentas n°11	presence of acute inflammation such as acute chorioamniotitis or funiculitis	through study completion, an average of one year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maternal first trimester biological markers n°1	PAPPA	through study completion, an average of one year
Maternal first trimester biological markers n°2	Beta HCG	through study completion, an average of one year
Maternal first trimester biological markers n°3	PlGF	through study completion, an average of one year
Course of the pregnancies n°1	single or twin pregnancy	through study completion, an average of one year
Course of the pregnancies n°2	use of aspirin or heparin during pregnancy	through study completion, an average of one year
Course of the pregnancies n°3	occurrence of pre-eclampsia	through study completion, an average of one year
Course of the pregnancies n°4	occurrence of IUGR	through study completion, an average of one year
Course of the pregnancies n°5	occurrence of stillbirth	through study completion, an average of one year
Course of the pregnancies n°6	occurrence of premature rupture of membrane	through study completion, an average of one year
Course of the pregnancies n°7	occurrence of gestational diabetes	through study completion, an average of one year
Course of the pregnancies n°8	term at delivery	through study completion, an average of one year
Course of the pregnancies n°9	mode of delivery	through study completion, an average of one year
Course of the pregnancies n°10	occurrence of disseminated intravascular coagulation	through study completion, an average of one year
Course of the pregnancies n°11	occurrence of postpartum haemorrhage	through study completion, an average of one year
maternal characteristics n°1	parity	through study completion, an average of one year
maternal characteristics n°2	previous vasculoplacental disorder	through study completion, an average of one year
maternal characteristics n°3	BMI before pregnancy	through study completion, an average of one year
maternal characteristics n°4	age at delivery	through study completion, an average of one year
maternal characteristics n°5	Tobacco use and drug use	through study completion, an average of one year
maternal characteristics n°6	chronic hypertension or chronic nephropathy	through study completion, an average of one year
maternal characteristics n°7	diabetes	through study completion, an average of one year
maternal characteristics n°8	APL syndrome or SLE	through study completion, an average of one year
maternal characteristics n°9	previous VTE event	through study completion, an average of one year
maternal characteristics n°10	blood group	through study completion, an average of one year
maternal characteristics n°11	mode of conception	through study completion, an average of one year
fetal characteristics n°1	newborn weight	through study completion, an average of one year
fetal characteristics n°2	sex	through study completion, an average of one year

Collaborators and Investigators

• Sponsor: University Hospital, Brest

Study record dates

Study Major Dates

• Study Start (Actual): September 23, 2019
• Primary Completion (Actual): September 23, 2019
• Study Completion (Actual): April 10, 2020

Study Registration Dates

• First Submitted: November 4, 2019
• First Submitted That Met QC Criteria: November 14, 2019
• First Posted (Actual): November 19, 2019

Study Record Updates

• Last Update Posted (Actual): September 11, 2020
• Last Update Submitted That Met QC Criteria: September 10, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Keywords: placental abruption
• Additional Relevant MeSH Terms: Pathologic Processes; Hemorrhage; Pregnancy Complications; Obstetric Labor Complications; Hematoma; Placenta Diseases; Abruptio Placentae
• Other Study ID Numbers: 29BRC19.0193

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No